Elsevier

Atherosclerosis

Volume 119, Issue 2, 26 January 1996, Pages 215-222
Atherosclerosis

An examination of the effect of combined cyclical hormone replacement therapy on lipoprotein(a) and other lipoproteins

https://doi.org/10.1016/0021-9150(95)05650-5Get rights and content

Abstract

Lipoprotein(a) (Lp(a)) is an independent marker of cardiovascular disease which is relatively unresponsive to treatment with most of the commonly prescribed lipid lowering drugs. Concentrations of Lp(a) increase after the menopause, and the primary aim of this study was to determine whether combined hormone replacement therapy was effective in lowering levels of Lp(a) in postmenopausal women. An open longitudinal study was conducted among 42 women who had undergone a spontaneous menopause and were attending the outpatient clinic of the Prince of Wales Hospital, Hong Kong. All subjects were treated with 2 mg oral estradiol daily and 5 mg medroxyprogesterone acetate for 12 days each calendar month. Fasting blood samples for lipoprotein measurement were taken before the commencement of treatment and at 6 and 12 months. Lp(a) levels showed a skewed distribution with a median value before treatment of 9.45 mg/dl (range 1.47–95.62 mg/dl). After 6 months, there was a reduction to 7.70 mg/dl (1.12–72.59 mg/dl) (P < 0.01), and after 12 months the median concentration was 7.14 mg/dl (0.63–69.23 mg/dl) (P < 0.001 0–12 months). There were also significant reductions in the concentrations of apo B from 116.13 to 111.62 mg/dl and LDL-C from 3.02 to 2.74 mmol/l (P < 0.05), plus a lowering of TC of borderline significance. Apo A-I increased from 162.56 to 173.35 mg/dl (P < 0.01), but there were no significant changes in HDL-C or the HDL-C subfractions. TC, LDL-C, apo B and TG concentrations were higher and HDL-C and HDL2-C concentrations were lower when blood was sampled during combined treatment with estrogen and progesterone than when estrogen was being taken alone. Levels of Lp(a) were also lower during the estrogen only phase of treatment, but none of these differences were statistically significant. This study demonstrates that combined cyclical hormone replacement therapy is effective in reducing concentrations of Lp(a). The trend towards a more atherogenic lipid profile during the combined phase of treatment suggests that attention should be given to the timing of blood sampling in future studies of this nature.

References (35)

  • MJ Van der Mooren et al.

    Beneficial effects on serum lipoproteins by 17β-oestradiol-dydrogesterone therapy in postmenopausal women; a prospective study

    Eur J Obstet Gynecol Reprod Biol

    (1992)
  • RG De Leon et al.

    Lipid and hormonal profile of Panamanian women during the menstrual cycle

    Int J Gynaecol Obstet

    (1992)
  • AM Lebech et al.

    Metabolic changes during the normal menstrual cycle: a longitudinal study

    Am J Obstet Gynecol

    (1990)
  • RD Gambrell

    Cancer and the use of estrogens

    Int J Fertil

    (1986)
  • BW Walsh et al.

    Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins

    N Engl J Med

    (1991)
  • EJ Schaefer et al.

    The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females

    J Clin Endocrinol Metab

    (1983)
  • RS Kushwaha et al.

    Effect of estrogen and progesterone in metabolism of apoprotein B in baboons

    Am J Physiol

    (1990)
  • Cited by (35)

    • Dyslipidemia in women after 50: Age, menopause or both?

      2009, Annales de Cardiologie et d'Angeiologie
    • Epidemiology and Risk Factors of Cardiovascular Disease in Postmenopausal Women

      2007, Treatment of the Postmenopausal Woman: Basic and Clinical Aspects, Third Edition
    • Update on cardiovascular disease in post-menopausal women

      2002, Best Practice and Research: Clinical Obstetrics and Gynaecology
    View all citing articles on Scopus
    View full text